Mg53 compositions and methods of use

Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

1 . An isolated anti-MG53 antibody comprising at least two complementarity determining regions (CDRs), wherein the antibody specifically binds to at least one amino acid residue selected from residues 1-477 of the amino acid sequence of at least one of SEQ ID NO: 1, 3, 5 or 7. 
     
     
         2 . The antibody of  claim 1 , wherein the antibody specifically binds to at least one amino acid residue selected from residues 1-144 of the amino acid sequence of at least one of SEQ ID NO: 1, 3, 5 or 7. 
     
     
         3 . The antibody of  claim 1 , wherein the antibody specifically binds to at least one amino acid residue selected from residues 2-62 of the amino acid sequence of at least one of SEQ ID NO: 1, 3, 5 or 7. 
     
     
         4 . The antibody of  claim 1 , wherein the antibody specifically binds to at least one amino acid residue selected from residues 2-268 of the amino acid sequence of at least one of SEQ ID NO: 1, 3, 5 or 7. 
     
     
         5 . The antibody of  claim 1 , wherein the antibody specifically binds to at least one amino acid residue selected from residues 246-477 of the amino acid sequence of at least one of SEQ ID NO: 1, 3, 5 or 7. 
     
     
         6 . The antibody of  claim 1 , wherein the anti-MG53 antibody is a member selected from the group consisting of a polyclonal antibody, a monoclonal antibody, and a bispecific antibody. 
     
     
         7 . The antibody of  claim 6 , wherein the antibody is monoclonal. 
     
     
         8 . The antibody of  claim 7 , wherein the monoclonal antibody is at least one of chimeric, humanized, or a fully human antibody. 
     
     
         9 . The antibody of  claim 8 , wherein the antibody is at least one of a single chain, a single domain, or a antibody fragment. 
     
     
         10 . The antibody of  claim 9 , wherein the fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2  fragment. 
     
     
         11 . The antibody of  claim 6 , wherein the bispecific antibody comprises at least one variable region capable of specifically binding MG53. 
     
     
         12 . The antibody of  claim 9 , wherein the single chain, single domain or antibody fragment comprises at least one heavy (H) chain variable region (VH) CDR. 
     
     
         13 . The antibody of  claim 9 , wherein the single chain, single domain or antibody fragment comprises at least one light (L) chain variable region (VL) CDR. 
     
     
         14 . The antibody of  claim 13 , wherein the light chain is a kappa chain or a lambda chain. 
     
     
         15 . The antibody of  claim 1 , wherein the antibody is a type selected from the group consisting of IgG, IgM, IgA, IgE and IgD. 
     
     
         16 . A composition comprising an effective amount of the antibody of  claim 1  and a pharmaceutically acceptable carrier or excipient. 
     
     
         17 . A method of treating or diagnosing an MG53-related condition comprising contacting or administering the composition of  claim 16  to a cell, tissue, organ or individual, wherein the composition is effective for treating or diagnosing the MG53-related condition. 
     
     
         18 . The method of  claim 17  wherein an amount of antibody administered to an the individual is from about 0.1 mg/kg to about 2000 mg/kg. 
     
     
         19 . The method of  claim 17 , wherein the antibody is administered by at least one route selected from intravenously, intraperitoneally, intramuscularly, and subcutaneously. 
     
     
         20 . An isolated and/or recombinant anti-MG53 antibody wherein the antibody specifically binds to an epitope within a polypeptide having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1. 
     
     
         21 . The antibody of  claim 20 , wherein the antibody specifically binds to an epitope within residues 1-144 of the amino acid sequence of SEQ ID NO: 1. 
     
     
         22 . An isolated nucleic acid encoding the antibody of  claim 1  or a portion thereof. 
     
     
         23 . A host cell comprising the nucleic acid of  claim 22 . 
     
     
         24 . The antibody of  claim 1 , wherein the antibody comprises at least one heavy chain or light chain CDR.